ORIC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Oric Pharmaceuticals Inc (ORIC) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While analysts have a positive outlook on the stock with high price targets and optimism around its drug pipeline, the lack of recent positive financial performance, insider and hedge fund selling, and no significant proprietary trading signals make it prudent to hold off on buying this stock at this time.
The MACD is below 0 and negatively contracting, suggesting bearish momentum. RSI is neutral at 65.397, and moving averages are converging, indicating no clear trend. The stock is trading near its resistance level (R1: 12.359) in pre-market, which could act as a barrier for further upward movement.
The next 12 months are expected to be catalyst-rich for the company.
Hedge funds and insiders are significantly increasing their selling activity, with insider selling up 773.65% in the last month. The company's financial performance is weak, with a YoY decline in net income (-15.98%) and EPS (-41.18%). No recent news or congress trading data provides additional support for a buy decision.
In Q4 2025, Oric Pharmaceuticals reported no revenue growth (0% YoY) and a net income decline to -$30.51 million (-15.98% YoY). EPS dropped to -0.3 (-41.18% YoY), reflecting ongoing financial struggles.
Analysts are bullish on the stock, with H.C. Wainwright, JPMorgan, and Cantor Fitzgerald reiterating 'Buy' or 'Overweight' ratings. Price targets range from $17 to $25, with optimism around the company's drug pipeline and potential catalysts in the next 12 months.
